Efficacy and Safety of Ipragliflozin, a selective SGLT2 inhibitor, in type 2 diabetes patients with insulin therapy
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000014968
- Lead Sponsor
- Tokyo Medical University Hospital Division of Diabetes,Metabolism and Endocrinology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Contraindiction for Ipragliflozin Patients who may have been pregnant or pregnant women Patients who are considered low-nutrition and dehydration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HbA1c
- Secondary Outcome Measures
Name Time Method fasting plasma glucose sCPR IRI LDLc HDLc TG urine protein urine keton body weight insulin dose hypoglycemia